Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$20.38 USD
-0.09 (-0.44%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $20.38 0.00 (0.00%) 7:50 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
Catalyst Pharmaceuticals, Inc. [CPRX]
Reports for Purchase
Showing records 141 - 160 ( 427 total )
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Firdapse Development and the Band Plays On, Despite Failure in MuSK-MG Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q20 Recap - Pipeline Snag, but Valuation Still Compelling
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Musings on LEMS Landscape as FDA Litigation Decision Expected 3Q20; Reit Buy and $9 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pandemic Impacts on Firdapse, With Further Upside and Pipeline Progress on Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q20 Recap - COVID-19 Headwinds Impacting Targets
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department